Get the Stockscreener App
7.40
2.00%
0.145
After Hours:
7.30
-0.10
-1.35%
89 Bio Inc stock is traded at $7.40, with a volume of 736.57K.
It is up +2.00% in the last 24 hours and down -22.11% over the past month.
89bio Inc is a United States-based clinical-stage biopharmaceutical company focused on the development and commercialization of therapies for the treatment of liver and cardio-metabolic diseases. Its product candidate, pegozafermin (previously BIO89-100), a specifically engineered glycoPEGylated analog of fibroblast growth factor 21 (FGF21), is currently being developed for the treatment of nonalcoholic steatohepatitis (NASH) and for the treatment of severe hypertriglyceridemia (SHTG).
See More
Previous Close:
$7.255
Open:
$7.18
24h Volume:
736.57K
Relative Volume:
1.06
Market Cap:
$776.32M
Revenue:
-
Net Income/Loss:
$-174.61M
P/E Ratio:
-3.5071
EPS:
-2.11
Net Cash Flow:
$-165.54M
1W Performance:
-3.52%
1M Performance:
-22.11%
6M Performance:
-36.43%
1Y Performance:
-52.07%
1-Day Range:
$7.18
$7.40
1-Week Range:
$7.18
$7.76
52-Week Range:
$6.575
$16.63
89 Bio Inc Stock (ETNB) Company Profile
Name
89 Bio Inc
Sector
Industry
Phone
(415) 432-9270
Address
142 SANSOME STREET, SAN FRANCISCO, CA
89 Bio Inc Stock (ETNB) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| May-12-22 | Upgrade | Raymond James | Outperform → Strong Buy |
| Dec-20-21 | Initiated | H.C. Wainwright | Buy |
| Oct-26-21 | Resumed | Cantor Fitzgerald | Overweight |
| Jul-29-21 | Resumed | BTIG Research | Buy |
| May-25-21 | Downgrade | Raymond James | Strong Buy → Outperform |
| Apr-21-21 | Initiated | Cantor Fitzgerald | Overweight |
| Oct-19-20 | Initiated | Raymond James | Strong Buy |
| Sep-25-20 | Upgrade | BofA Securities | Neutral → Buy |
| Jul-31-20 | Initiated | Piper Sandler | Overweight |
| Jul-23-20 | Initiated | BTIG Research | Buy |
| Jul-07-20 | Initiated | Chardan Capital Markets | Buy |
| Dec-09-19 | Initiated | BofA/Merrill | Neutral |
| Dec-09-19 | Initiated | Oppenheimer | Outperform |
| Dec-09-19 | Initiated | RBC Capital Mkts | Outperform |
| Dec-09-19 | Initiated | SVB Leerink | Outperform |
View All
89 Bio Inc Stock (ETNB) Latest News
The Potential Rise in the Price of 89bio Inc (ETNB) following insiders activity - Knox Daily
89bio to Participate in the H.C. Wainwright 8th Annual MASH Investor Conference - StockTitan
What is 89bio Inc (ETNB) Stock Return on Shareholders’ Capital? - SETE News
Metric Deep Dive: Understanding 89bio Inc (ETNB) Through its Ratios - The Dwinnex
Severe Hypertriglyceridemia Market Growth to Accelerate in Forecast Period (2024-2034), DelveInsight Analyzes | Ionis Pharma, 89bio, Inc., Arrowhead Pharma, Hightide Therapeutics, AstraZeneca, Kowa - Barchart
Severe Hypertriglyceridemia Market Growth to Accelerate - openPR
89Bio's SWOT analysis: pegoza's potential in competitive MASH market - Investing.com
89Bio's SWOT analysis: pegoza's potential in competitive MASH market By Investing.com - Investing.com UK
Health Check: How Prudently Does 89bio (NASDAQ:ETNB) Use Debt? - Simply Wall St
89bio Inc (ETNB) did well last session? - US Post News
In the Green: 89bio Inc (ETNB) Closes at 7.67, Up/Down -6.35 from Previous Day - The Dwinnex
89bio (NASDAQ:ETNB) Trading Down 2.9% - MarketBeat
89bio (NASDAQ:ETNB) Trading Down 2.9% - Defense World
89bio, Inc. (NASDAQ:ETNB) Receives $30.14 Average PT from Brokerages - MarketBeat
Adversity is less terrifying than hope: 89bio Inc (ETNB) - SETE News
Integral Health Asset Management LLC Buys 150,000 Shares of 89bio, Inc. (NASDAQ:ETNB) - MarketBeat
89bio's (ETNB) "Overweight" Rating Reiterated at Cantor Fitzgerald - MarketBeat
Balakrishna pays tribute to ANR on his 100th Birth Anniversary - TrackTollywood
Oruka Therapeutics (NASDAQ:ORKA) Stock Quotes, Forecast and News Summary - Benzinga
89bio Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - StockTitan
Saba capital management sells shares in Eaton Vance trust worth over $484k - Investing.com
Ratio Examination: 89bio Inc (ETNB)’s Price-to-Cash and Price-to-Free Cash Flow - The Dwinnex
Teresa Perney brought in to lead 89bio’s regulatory strategy - The Pharma Letter
Bank of New York Mellon Corp Has $2.40 Million Stake in 89bio, Inc. (NASDAQ:ETNB) - Defense World
Peter Maag resigns as Kyverna CEO - BioCentury
89bio Announces Appointment of Teresa Perney, Ph.D. as Chief Regulatory and Quality Officer - ForexTV.com
89bio Announces Appointment of Teresa Perney, Ph.D. as Chief Regulatory and Quality Officer - StockTitan
Positive Pooled Data from Nuvation Bio’s TRUST-I and TRUST-II Studies Highlight Taletrectinib’s Best-in-Class Potential for Patients with Advanced ROS1-positive NSCLC, Supporting Planned New Drug Application Submission in the Fourth Quarter of 2024 - BioSpace
Positive Pooled Data from Nuvation Bio’s TRUST-I and TRUST-II Studies Highlight Taletrectinib’s Best-in-Class Potential for Patients with Advanced ROS1-positive NSCLC, Supporting Planned New Drug Application Submission in the Fourth Quarter of 2024 - Business Wire
Positive Pooled Data from Nuvation Bio’s TRUST-I and TRUST-II Studies Highlight Taletrectinib’s Best-in-Class Potential for Patients with Advanced ROS1-positive NSCLC, Supporting Planned New Drug Application Submission in the Fourth Quarter of 2024 - Yahoo Finance
ETNB’s Market Quandary: Decoding the Ups and Downs of 2023 - The InvestChronicle
Upward Trajectory: Gossamer Bio Inc (GOSS) Posts a Slidee, Closing at 0.89 - The Dwinnex
ETNB (89bio Inc) may reap gains as insiders became active recently - Knox Daily
MicroRNA Market to Surge $6.11 Bn by 2034 Driven by Healthy 12.89% CAGR - BioSpace
89bio Inc (ETNB)’s results reveal risk - US Post News
Financial Metrics Check: 89bio Inc (ETNB)’s Ratios for Trailing Twelve Months - The Dwinnex
89bio, Inc. (NASDAQ:ETNB) Stock Position Raised by Candriam S.C.A. - MarketBeat
89bio Inc [ETNB] Shares Rise 0.23 % on Wednesday - Knox Daily
Raymond James & Associates Grows Position in 89bio, Inc. (NASDAQ:ETNB) - Defense World
89bio Inc (ETNB) is an excellent investment, but the stock is overvalued/undervalued right now - US Post News
Short Interest in 89bio, Inc. (NASDAQ:ETNB) Expands By 5.2% - MarketBeat
Insider Sale Alert: 89bio Inc [ETNB] – Is it Time to sell? - Knox Daily
Deadline passes for FBI to hand over documents related to Tim Walz's alleged 'long standing' China connection - LatinTimes
ETNB Stock Sees Surge of Approximately 1.12% in Last Five Days - Knox Daily
Cardiac Bio Implant Devices Market Size Hits USD 130.89 Billion by 2032 | CAGR of 10.61% - openPR
89bio, Inc. (NASDAQ:ETNB) Receives $30.14 Average PT from Analysts - MarketBeat
89bio Inc (ETNB)’s stock chart: A technical perspective - US Post News
89bio to Participate in Upcoming Investor Conferences - StockTitan
KRX Growth Companies With High Insider Ownership Growing Earnings Up To 99% - Simply Wall St
3 KRX Growth Companies Insiders Are Betting On - Simply Wall St
Examining the Potential Price Growth of 89bio Inc (ETNB) - Knox Daily
89 Bio Inc Stock (ETNB) Financials Data
Revenue
Net Income
Cash Flow
EPS
0.05%
4.86%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):